Scientists Identify Molecule Driving One of the Deadliest Forms of Breast Cancer
Australian researchers have identified a molecular switch, miR-342, that drives the spread of aggressive triple-negative breast cancer. The study suggests that existing drugs like palbociclib could be repurposed to treat patients with low levels of this molecule.
Why it matters
This discovery offers a potential new therapeutic pathway for one of the most difficult-to-treat forms of breast cancer, potentially improving patient outcomes.
Associate Professor Philip Gregory from the Centre for Cancer Biology at Adelaide University.
Co-senior author, Professor Robin Anderson (centre), from the Olivia Newton-John Cancer Research Institute, pictured with colleagues Caroline Bell and Dr Charlotte Roelofs.
Newswise — Australian researchers have uncovered a promising new way to tackle one of the most aggressive forms of breast cancer, raising hopes for more effective treatments to stop the disease from spreading.
The study, undertaken by Adelaide University and the Olivia Newton-John Cancer Research Institute , has identified a molecular switch that drives the spread of triple-negative breast cancer (TNBC) - the subtype responsible for some of the poorest outcomes because it lacks the hormone receptors that make many other breast cancers treatable with existing therapies that target these receptors.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in